Variable response to propranolol therapy for infantile hemangiomas
نویسندگان
چکیده
منابع مشابه
Topical propranolol therapy for infantile hemangiomas.
The nonselective beta-adrenergic receptor antagonist propranolol is an effective therapy for infantile hemangiomas. Systemic propranolol therapy shows a rapid therapeutic effect with good drug tolerability. We report on the efficacy of local application of propranolol ointment in superficial hemangiomas of the skin. In our outpatient department, 45 children with 65 hemangiomas were treated with...
متن کاملPropranolol for Infantile Hemangiomas
Hemangiomas are common vascular birthmarks that usually present a predictable pattern of proliferation and ultimate involution. Most do not require any treatment. When intervention is clinically indicated, medical and surgical options exist. Historically, corticosteroids have been used and have been shown to slow or stop the growth of a majority of hemangiomas; however, growth concerns and infe...
متن کاملPropranolol for treatment of infantile hemangiomas*
Infantile hemangioma is the most common vascular tumor in early childhood. Propranolol has been successfully used recently in a limited number of children with Infantile hemangioma. We present 6 cases of Infantile hemangioma, at a single dermatological center, which responded to oral propranolol with good results.
متن کاملPropranolol for infantile hemangiomas in developing countries.
BACKGROUND Propranolol is the treatment of choicefor complicated infantile hemangiomas (IH). However,in some locations, propranolol has not yet becomestandard of care. To our knowledge, until 2014,propranolol had not been used in Afghanistan totreat IH. OBJECTIVES To raise further awareness thatpropranolol is the treatment of choice for complicatedIH, suggest a propranolol induction, maintena...
متن کاملRebound Growth of Infantile Hemangiomas After Propranolol Therapy.
BACKGROUND AND OBJECTIVES Propranolol is first-line therapy for problematic infantile hemangiomas (IHs). Rebound growth after propranolol discontinuation is noted in 19% to 25% of patients. Predictive factors for rebound are not completely understood and may alter the management approach. The goal of the study was to describe a cohort of patients with IHs treated with propranolol and to identif...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Dermatology
سال: 2012
ISSN: 0019-5154
DOI: 10.4103/0019-5154.94281